View clinical trials related to Nocturia.
Filter by:The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with nocturia.
This is a confirmation of safety profile for Minirin Melt in clinical practice.
This is a confirmation of safety profile for Minirin Melt in clinical practice.
This is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group comparative trial to be conducted in nocturia patients. The trial is designed to characterize the dose-response relationship of Minirin (desmopressin) Melt in order to establish correct dose recommendations in the target patient population. In particular, the trial is designed to link the duration of action to the clinical endpoint. Furthermore, the trial is designed to describe the safety of four different dose levels of desmopressin.
The purpose of this study is to describe the pharmacokinetics and pharmacodynamics of VA106483 in female subjects.
To investigate the effect of VA106483 on nocturia related clinical outcomes compared to placebo.
The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.